Actively Recruiting
Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)
Led by Gruppo Italiano Malattie EMatologiche dell'Adulto · Updated on 2025-08-13
397
Participants Needed
2
Research Sites
229 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This multicenter, prospective and retrospective observational study aims to evaluate the use and efficacy of new drugs or their combinations in real-life in a population of adult AML patients.
CONDITIONS
Official Title
Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older
- Diagnosed with Acute Myeloid Leukemia (excluding M3 subtype) according to ELN guidelines
- Signed informed consent, if applicable
- Starting treatment with new AML drugs or combinations authorized by AIFA, including gilteritinib, IDH inhibitors, oral azacytidine maintenance, glasdegib, gemtuzumab ozogamicin, or other novel approved treatments up to 31.12.2027
You will not qualify if you...
- Participation in interventional clinical trials
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Ematologia Ente Ecclesiastico Casa Sollievo Della Sofferenza
San Giovanni Rotondo, Italy
Actively Recruiting
2
UOC Ematologia AOU di SASSARI
Sassari, Italy
Actively Recruiting
Research Team
P
Paola Fazi
CONTACT
E
Enrico Crea
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here